Cantor Fitzgerald initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and $74 price target
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MNPR:
- Monopar Therapeutics initiated with a Buy at Chardan
- Monopar Therapeutics, EDNOC announce EAP for MNPR-101-Zr, MNPR-101-Lu
- Salesforce initiated, Dollar Tree upgraded: Wall Street’s top analyst calls
- Monopar Therapeutics initiated with a Buy at Lucid Capital
- Monopar Therapeutics announces inclusion in Russell 3000, Russell 2000